The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis
Key facts
- Where
- Ostrava, CsehországSee the site
- Phase
- 4. fázis
Where in Csehország
- Fakultni nemocnice OstravaOstrava, CsehországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fakultni Nemocnice Ostrava
- Trial code
- EU 2024-514549-12-00
- Record updated
- 2025. szeptember 5.
- Original description
To determine whether and how serum OCR concentrations correlate with selected paraclinical and clinical indicators in patients with relapsing-remitting and/or primary progressive MSRead full original descriptionShow less
To determine whether and how serum OCR concentrations correlate with selected paraclinical and clinical indicators in patients with relapsing-remitting and/or primary progressive MS
Inclusion: Patients diagnosed with RR and/or PP RS with already established or newly started OCR treatment; Men and women older than 18 years; Signing the Informed Consent to participate in the study; Female patients of childbearing age who can become pregnant must have a negative result of serum human chorionic gonadotropin (hCG) at the initial visit and use a highly reliable method of contraception with a home control urine pregnancy test every month for the entire duration of the study.
Exclusion: Hypersensitivity to the medicinal substance or to any excipient; Current active infection; Known active malignant disease; Patients in a severe immunocompromised state; Pregnancy or breastfeeding.